Republic of Korea-based biopharma company Celltrion is looking to accelerate its momentum in Europe; analysts belive that the company could receive the European Medicines Agency’s (EMA) approval to market its biosimilar of Roche’s blockbuster cancer treatment, Herceptin (trastuzumab), by March 2018.
Republic of Korea-based biopharma company Celltrion is looking to accelerate its momentum in Europe; according to The Investor, analysts believe that the company could receive the European Medicines Agency’s (EMA) approval to market its biosimilar of Roche’s blockbuster cancer treatment, Herceptin (trastuzumab), by March 2018.
Celltrion’s proposed trastuzumab biosimilar is the company’s third biosimilar product pursuing access to the European market, following the launch of Remsima, an infliximab biosimilar of Johnson & Johnson’s reference Remicade, and a rituximab biosimilar, Truxima, referenced on Rituxan.
“Herzuma will be well positioned for Celltrion to have confidence in sales based on 4 years of market experience (in Europe) and a strong partner network,” Park Si-hyeong, an analyst at IBK Securities, told The Investor.
Most recently, the FDA approved Mylan and Biocon's trastuzumab biosimilar, Ogivri. Other Herceptin products in development for the US and EU markets include:
In addition to its trastuzumab biosimilar, Celltrion is developing several other notable products:
The Investor reports that an official at Celltrion has indicated that Herzuma will be able to hit the European market 3 months after approval. Celltrion has not decided yet on its marketing partner for the drug, but it is likely to continue to work with existing partners such as Mundipharma, Biogaran, and Kern Pharma.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.